Prognostic significance of systemic immune‐inflammation index in patients with nonfunction pancreatic neuroendocrine tumor undergoing surgical resection

Abstract Purpose The purpose of our study was to investigate the clinical significance and prognostic role of the systemic immune‐inflammation index (SII) in patients who underwent surgical resection for nonfunctioning pancreatic neuroendocrine tumors (pNETs). Methods We conducted a retrospective analysis of 364 patients with nonfunctioning pNETs. The association between the SII level and clinical parameters was investigated. The receiver operating characteristic (ROC) curve was used to calculate the optimal SII value. Cox proportional hazard analysis was performed to evaluate the prognostic factors. Results Our study included 364 patients with nonfunctioning pNETs who underwent surgery. The median age was 51.0 (43.0, 59.3), and 164 (45.1%) were male. The optimal threshold of SII determined by ROC analysis was 523.95. Higher SII levels were significantly associated with older age ( p = 0.001), sex ( p = 0.011), tumor size ( p = 0.032), and tumor grade ( p = 0.002). Recurrence was observed in 70 (19.2%) patients following a median follow‐up of 98 months. Univariate analysis showed that higher SII ( p < 0.0001), tumor size >4 cm ( p = 0.015), and G2/G3 grade ( p = 0.002) were significantly associated with disease‐free survival (DFS). Multivariate analysis revealed that higher SII (HR: 7.35; 95% CI: 3.44, 15.70; p < 0.0001) and G2/G3 grade (HR: 3.11; 95% CI: 1.42, 6.82; p = 0.005) remained significantly associated with tumor recurrence. Furthermore, 46 (12.6%) patients died during the follow‐up. Higher SII (HR: 8.43; 95% CI: 3.19, 22.72; p < 0.0001) and G2/G3 grade (HR: 3.16; 95% CI: 1.01, 9.86; p = 0.048) were independent predictors of overall survival (OS) by multivariate analysis. Conclusion In conclusion, our study revealed that a higher SII level was associated with tumor‐related features (larger tumor size and advanced grade) and subsequent shorter DFS and OS in patients with nonfunctioning pNETs. These results indicated that the SII could serve as an efficient prognostic biomarker for nonfunctioning pNETs.